Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells

Molecular Cancer Research

Volumn 6, Issue 11, 2008, Pages 1775-1785

  Warrenfeltz, Susanne W ^a   Lott, Stephen A ^a   Palmer, Travis M ^a   Gray, Judy C ^a   Puett, David ^a  

^a University of Georgia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORSKOLIN; LUTEINIZING HORMONE; METALLOPROTEINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE C;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL SURFACE; GENE EXPRESSION; GENE OVEREXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CANCER; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; SECOND MESSENGER; UPREGULATION; WESTERN BLOTTING;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIC AMP; FEMALE; FORSKOLIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; INOSITOL PHOSPHATES; LUTEINIZING HORMONE; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; RECEPTORS, LH; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 56449089065     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0214     Document Type: Article

References (63)

1. Richards JS. Ovulation: new factors that prepare the oocyte for fertilization. Mol Cell Endocrinol 2005;234:75-9.
2. Richards JS, Russell DL, Robker RL, Dajee M, Alliston TN. Molecular mechanisms of ovulation and luteinization. Mol Cell Endocrinol 1998;145:47-54.
3. Curry TE, Jr., Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003;24:428-65.
4. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
5. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004;5:19-24.
6. Schiffenbauer YS, Meir G, Maoz M, Even-Ram SC, Bar-Shavit R, Neeman M. Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by A(v)-integrin. Gynecol Oncol 2002;84:296-302.
7. Kuroda H, Mandai M, Konishi I, et al. Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of upregulation of insulin-like growth factor-1by hCG. Int J Cancer 1998;76:571-8.
8. Kuroda H, Mandai M, Konishi I, et al. Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and hCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1. Int J Cancer 2001;91:309-15.
9. Tashiro H, Katabuchi H, Begum M, et al. Roles of luteinizing hormone/ chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. Cancer Sci 2003;94:953-9.
10. Zygmunt M, Herr F, Keller-Schoenwetter S, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002;87:5290-6.
11. Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC, Paulson RJ. Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril 2002;78:1096-9.
12. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76.
13. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr Relat Cancer 2005;12:407-21.
14. Ascoli M, Puett D. The gonadotropin hormones and their receptors, 6th of Yen and Jaffe edition. Philadelphia (PA): Elsevier Publishing; 2008.
15. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev 2002;23:141-74.
16. Hirakawa T, Ascoli M. A constitutively active somatic mutation of the human lutropin receptor found in Leydig cell tumors activates the same families of G proteins as germ line mutations associated with Leydig cell hyperplasia. Endocrinology 2003;144:3872-8.
17. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 2007;213:589-602.
18. Freimann S, Ben-Ami I, Dantes A, Ron-El R, Amsterdam A. EGF-like factor epiregulin and amphiregulin expression is regulated by gonadotropins/ cAMP in human ovarian follicular cells. Biochem Biophys Res Commun 2004;324:829-34.
19. Park JY, Su YQ, Ariga M, Law E, Jin SL, Conti M. EGF-like growth factors as mediators of LH action in the ovulatory follicle. Science 2004;303:682-4.
20. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65.
21. Mass RD. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 2004;58:932-40.
22. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A 2002; 99:15937-40.
23. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004;58:903-13.
24. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
25. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
26. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
27. Johnston JB, Navaratnam S, Pitz MW, et al. Targeting the EGFR pathway for cancer therapy. Curr Med Chem 2006;13:3483-92.
28. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21.
29. Fregien NL, White LA, Bunge MB, Wood PM. Forskolin increases neuregulin receptors in human Schwann cells without increasing receptor mRNA. Glia 2005;49:24-35.
30. Bates NP, Hurst HC. Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland. J Mammary Gland Biol Neoplasia 1997;2:153-63.
31. Simon WE, Albrecht M, Hansel M, Dietel M, Holzel F. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 1983;70:839-45.
32. Zheng W, Lu JJ, Luo F, et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000;76:80-8.
33. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
34. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-6.
35. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
36. Lu JJ, Zheng Y, Kang X, et al. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 2000;79: 158-68.
37. Meduri G, Charnaux N, Loosfelt H, et al. Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res 1997;57:857-64.
38. Pabon JE, Bird JS, Li X, et al. Human skin contains luteinizing hormone/ chorionic gonadotropin receptors. J Clin Endocrinol Metab 1996;81:2738-41.
39. Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV. Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. J Clin Endocrinol Metab 1996;81:2397-400.
40. Choi JH, Wong AS, Huang HF, Leung PC. Gonadotropins and ovarian cancer. Endocr Rev 2007;28:440-61.
41. Hogdall EV, Christensen L, Kjaer SK, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98:66-73.
42. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
43. Choi JH, Choi KC, Auersperg N, Leung PC. Overexpression of folliclestimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2004;89:5508-16.
44. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001;61:2420-3.
45. McKenzie SJ, DeSombre KA, Bast BS, et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 1993;71:3942-6.
46. King BL, Carter D, Foellmer HG, Kacinski BM. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am J Pathol 1992;140:23-31.
47. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993;53:891-8.
48. Hsieh SS, Malerczyk C, Aigner A, Czubayko F. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int J Cancer 2000;86:644-51.
49. Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2001;172:213-22.
50. Shi H, Segaloff DL. A role for increased lutropin/choriogonadotropin receptor (LHR) gene transcription in the follitropin-stimulated induction of the LHR in granulosa cells. Mol Endocrinol 1995;9:734-44.
51. Peyrat JP, Meusy-Dessolle N, Garnier J. Changes in Leydig cells and luteinizing hormone receptors in porcine testis during postnatal development. Endocrinology 1981;108:625-31.
52. Chen H, Hardy MP, Zirkin BR. Age-related decreases in Leydig cell testosterone production are not restored by exposure to LH in vitro. Endocrinology 2002;143:1637-42.
53. Shan LX, Hardy MP. Developmental changes in levels of luteinizing hormone receptor and androgen receptor in rat Leydig cells. Endocrinology 1992;131:1107-14.
54. Catt KJ, Dufay ML. Gonadotropic hormones: biosynthesis, secretion, receptors, and actions in reproductive endocrinology. 3rd ed. In: Yen SSC, Jaffre RB. Reproductive endocrinology. Philadelphia: WB Saunders Co; 1991. p. 105-55.
55. Angelova K, Narayan P, Simon JP, Puett D. Functional role of transmembrane helix 7 in the activation of the heptahelical lutropin receptor. Mol Endocrinol 2000;14:459-71.
56. Angelova K, Fanelli F, Puett D. Contributions of intracellular loops 2 and 3 of the lutropin receptor in Gs coupling. Mol Endocrinol 2008;22:126-38.
57. Angelova K, Fanelli F, Puett D. A model for constitutive lutropin receptor activation based on molecular simulation and engineered mutations in transmembrane helices 6 and 7. J Biol Chem 2002;277:32202-13.
58. New DC, Wong YH. Molecular mechanisms mediating the G proteincoupled receptor regulation of cell cycle progression. J Mol Signal 2007;2:2.
59. Shiraishi K, Ascoli M. A co-culture system reveals the involvement of intercellular pathways as mediators of the lutropin receptor (LHR)-stimulated ERK1/2 phosphorylation in Leydig cells. Exp Cell Res 2008;314:25-37.
60. Aguilar Z, Akita RW, Finn RS, et al. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 1999;18:6050-62.
61. Rao Ch V, Li X, Manna SK, Lei ZM, Aggarwal BB. Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-κB and AP-1act ivation. J Biol Chem 2004;279:25503-10.
62. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 2005;65:6801-10.
63. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDC(T)) method. Methods 2001; 25:402-8.